Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Data to inform surveillance and treatment for leukemia predisposition syndromes are limited and recommendations largely based on expert opinion. This study aimed to investigate the clinical features and outcomes of myelodysplastic syndrome and acute myeloid leukemia in Shwachman Diamond syndrome, an inherited marrow failure disorder with high risk of myeloid malignancy. Methods: We performed a multicentre, retrospective cohort study in 17 centres in the USA and Canada. Patients with a genetic or clinical diagnosis of Shwachman Diamond syndrome who developed myelodysplastic syndrome or acute myeloid leukemia were eligible without additional restriction. Medical records from March 1, 2001 to October 5, 2017 were reviewed for 36 patients. Blinded central review of bone marrow pathology was performed in 27 available cases. Description of clinical features and survival assessment was performed. Median follow-up was 4·9 years (range: 0.3–10.1, IQR: 3.9–8.4). Findings: Median age was 18 years (range: 0.5–47.0, IQR:10–24). Central pathology review concurred with local diagnosis in 56% (n=15/27). Treatment was heterogeneous with 10 chemotherapy regimens and 16 hematopoietic stem cell transplant regimens. Only 1 of 10 initially treated with chemotherapy for leukemia achieved complete remission. Median survival from myelodysplastic syndrome / leukemia diagnosis was 0·99 years in leukemia (95% CI: 0.2–2.4, IQR: 0.6–1.1) and 7·7 years in myelodysplastic syndrome (95% CI: 0.8-NA; IQR: 0.7-NA). Overall survival at 3 years was 11% (95% CI:1–39, n=10) and 51% (95% CI:29–68, n=26) for leukemia and myelodysplastic syndrome respectively. Bone marrow surveillance was conducted in 33% (n=3/9) of leukemia and 46% (n=11/24) of myelodysplastic syndrome subjects. Individuals monitored with bone marrow surveillance prior to myelodysplastic syndrome / leukemia diagnosis had a 3-year OS of 62% (95% CI: 32–82, n=14) compared with 28% without surveillance (95% CI:10–50, n=19) (p=0·13). Several patients developed myelodysplastic syndrome in the setting of stable blood counts (n=6). Interpretation: Prognosis is poor for Shwachman Diamond syndrome patients with leukemia due to both therapy-resistant disease and treatment-related toxicities. Improved surveillance algorithms for early disease detection/risk stratification, biological studies of clonal evolution and prospective clinical trials are needed to inform effective prevention and treatment strategies for leukemia predisposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Self-citationTP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776
Cited by
Cazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 491
Convergent somatic evolution commences in utero in a germline ribosomopathy
Machado, H. E., Øbro, N. F., Williams, N., Tan, S., Boukerrou, A. Z., Davies, M., Belmonte, M., Mitchell, E., Baxter, E. J., Mende, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40896-5 · Cited by 26
Metadata
- Authors
- Myers, K. C., Furutani, E., Weller, E., Siegele, B., Galvin, A., Arsenault, V., Alter, B. P., Boulad, F., Bueso-Ramos, C., Burroughs, L., Castillo, P., Connelly, J., Davies, S. M., DiNardo, C. D., Hanif, I., Ho, R. H., Karras, N., Manalang, M., McReynolds, L. J., Nakano, T. A., Nalepa, G., Norkin, M., Oberley, M. J., Orgel, E., Pastore, Y. D., Rosenthal, J., Walkovich, K., Larson, J., Malsch, M., Elghetany, M. T., Fleming, M. D., & Shimamura, A.
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 7
- Issue
- 3
- Pages
- e238-e246
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W2997806446
- Cited by
- 119
- References
- 5
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. https://app.cochat.ai/papers/10.1016/s2352-3026(19)30206-6
- The paper
- Myers, K. C., Furutani, E., Weller, E., Siegele, B., Galvin, A., Arsenault, V., Alter, B. P., Boulad, F., Bueso-Ramos, C., Burroughs, L., Castillo, P., Connelly, J., Davies, S. M., DiNardo, C. D., Hanif, I., Ho, R. H., Karras, N., Manalang, M., McReynolds, L. J., . . . Shimamura, A. (2020). Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(19)30206-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.